Abstract:Alzheimer's disease (AD) is initially and primarily associated with the degeneration and alteration in the metabolism of cholinesterases (ChEs). The use of ChEs inhibitors to treat Alzheimer's condition, on the basis of the cholinergic hypothesis of the disease, is, therefore, without grounds. Most disturbing is the fact that the currently available anti-ChEs are designed to inhibit normal ChEs in the brain and throughout the body, but not the abnormal ones. Based on the acetylcholinesterase (AChE) deficiency theory, treatment should be designed to protect the cranial ChEs system from alteration and/or to help that system fight against degeneration through restoring its homeostatic action for brain structure and function instead. The overlap in the clinical, biochemical, molecular-cellular, and pathological alterations seen in patients with AD and individuals with many other brain disorders, which has bewildered many investigators, may now be explained by the shared underlying mismetabolism of brain ChEs. The abnormal metabolism of ChEs existing in asymptomatic subjects may indicate that the system is "at risk" and deserves serious attention. Future perspectives of ChEs research in vivo and in vitro in connection with AD and clinical diagnosis, prevention and treatment are proposed. Several potentially useful therapeutic and preventive means and pharmacological agents in this regard are identified and discussed, such as physical and intellectual stimulation, and a class of drugs including vitamin E, R-(-)-deprenyl (deprenyl, selegiline), acetyl L-carnitine, cytidine diphosphocholine (CDP-choline), centrophenoxine, L-phenylalanine, naloxone, galactose, and lithium, that have been proven to be able to stimulate AChE activity. Their working mechanisms may be through directly changing the configuration of AChE molecules and/or correcting micro- and overall environmental biological conditions for ChEs.

Choline Transporters and The Pathogenesis of Alzheimer's Disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Role of Cholinergic Signaling in Alzheimer’s Disease

Cholesterol involvement in the pathogenesis of neurodegenerative diseases

The Intersection of cerebral cholesterol metabolism and Alzheimer's disease: Mechanisms and therapeutic prospects

Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research

Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease

Sensitivity of Substrate Translocation in Chaperone-Mediated Autophagy to Alzheimer’s Disease Progression

Targeting Synaptic Pathology in Alzheimer’s Disease

Alpha 7 Nicotinic Acetylcholine Receptor and Its Effects on Alzheimer's Disease

Neurotransmitters in Prevention and Treatment of Alzheimer's Disease

New Insights Into the Pathogenesis of Alzheimer's Disease

Cholinesterases and the Pathology of Alzheimer Disease

Sensitivity of substrate translocation in chaperone-mediated autophagy to Alzheimer's disease progression

Brain cholinesterases: III. Future perspectives of AD research and clinical practice

Choline Supplementation Ameliorates Behavioral Deficits and Alzheimer's Disease-Like Pathology in Transgenic APP/PS1 Mice

Zinc Transporters in Alzheimer’s Disease

The Role of Cholesterol Metabolism in Alzheimer’s Disease

Trafficking Regulation of Proteins in Alzheimer’s Disease

Involvement Of Cerebrovascular Abnormalities In The Pathogenesis And Progression Of Alzheimer'S Disease: An Adrenergic Approach

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease